Special Drug Use-Results Survey of Gonalef (Subcutaneous injection 75/150, Subcutaneous injection pen 300/450/900) for Ovulation Induction in Patients with Anovulation or Oligo-Ovulation Accompanying Hypothalamic-Pituitary Dysfunction or Polycystic Ovary Syndrome Patients
Phase 4
- Conditions
- Ovulation Induction in Patients with Anovulation or Oligo-Ovulation Accompanying Hypothalamic-Pituitary Dysfunction or Polycystic Ovary Syndrome (OI)
- Registration Number
- JPRN-UMIN000033665
- Lead Sponsor
- Merck Serono Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who do not give a full consent to this survey.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method